Merck Sharp & Dohme Llc

This study tested a new version of an experimental vaccine called V118 in healthy adults. The main goal was to check how safe it was and how well people's bodies responded to it. Researchers gave the vaccine to 65 volunteers and closely monitored them for any side effects.

This study tested a new pneumonia vaccine called V116 in adults aged 18-64 who have a higher risk of getting sick from pneumococcal bacteria, such as those with diabetes, heart, lung, or kidney disease. Researchers compared V116 to a combination of two existing vaccines to see if…

This study tested a new vaccine called V330 designed to protect against norovirus, a common stomach bug. Researchers gave the vaccine to 245 healthy adults aged 18-49 and 60-79 to check if it's safe and if it triggers the body to produce protective antibodies. This was an early s…

This study tested a new vaccine called V116 to see if it is safe and creates a strong immune response in children and teenagers who are at higher risk for pneumococcal disease. It involved 882 participants aged 2 to 17 who had already received their routine childhood pneumococcal…

This study tested a new vaccine called V116 designed to protect against pneumococcal disease, which can cause pneumonia and other serious infections. It was compared directly to an existing vaccine (PPSV23) in over 1,400 adults aged 50 and older who had never received a pneumococ…

This study tested whether it is safe and effective to give the first doses of the HPV vaccine and the Moderna COVID-19 vaccine at the same doctor's visit to children aged 9 to 11. Researchers compared giving both shots together versus giving them separately to see if the body's i…

This study tested if people with well-controlled HIV could safely switch from a standard three-drug daily pill to a new two-drug daily pill. Researchers compared the new combination (doravirine/islatravir) against continuing the original treatment to see if it kept the virus supp…

This study tested whether a new daily pill called MK-8189 could safely reduce symptoms in adults experiencing a sudden worsening of schizophrenia. About 500 participants took either MK-8189, a placebo, or an existing antipsychotic for 6 weeks to compare their effects. The main go…

This early-stage study tested a single injection of an experimental drug called MK-2060 in people with advanced kidney disease. The main goals were to check the drug's safety, see how long it stays in the body, and measure its effect on blood clotting. Only 14 people with stage 4…

This was a first-in-human study to test the safety and early signs of effectiveness of a new drug called MK-4830. It was given alone and in combination with an existing immunotherapy (pembrolizumab) to 470 people with various advanced solid tumors that had stopped responding to s…

This large, completed Phase 3 trial compared a new two-drug combination (pembrolizumab and lenvatinib) against standard chemotherapy for women with advanced or recurrent endometrial (uterine) cancer. The main goal was to see if the drug combination could help patients live longer…

This early-stage study tested the safety of a new cancer drug called MK-4700, both alone and combined with an existing immunotherapy (pembrolizumab). The trial involved just 5 people with advanced solid tumors that had stopped responding to standard treatments. Researchers measur…

This study tested a new combination drug (MK-4280A) to see if it could help people with certain advanced cancers. It involved 163 people with either a type of advanced skin cancer (cSCC) or a type of endometrial cancer that had spread or returned. The goal was to see if the drug …

This study tested a combination of two drugs, pembrolizumab and lenvatinib, for people with an advanced form of kidney cancer that had spread and had not been treated before. The goal was to see how well the drugs worked together to shrink tumors and control the cancer. Researche…

This was an early safety study of a new drug, MK-1167, for Alzheimer's disease. It involved 28 patients who were already taking a standard Alzheimer's medication (donepezil). The main goals were to check for side effects and see how the drug is processed by the body over 24 hours…

This study tested whether adding an investigational drug called Sotatercept to a patient's existing pulmonary arterial hypertension (PAH) medications could improve their condition. It involved 46 Japanese adults with PAH who were already on stable background therapy. The main goa…

This first-in-human study tested the safety and dosing of a new experimental drug called MK-4464, both alone and combined with an existing immunotherapy (pembrolizumab). It involved 64 adults with advanced solid tumors that had spread and who had run out of standard treatment opt…

This early-stage study aimed to find a safe dose and understand how the body processes a new experimental drug called boserolimab. It involved 182 adults with advanced cancers, including lung and breast cancer, who had run out of standard treatment options. Researchers tested bos…

This early-stage study tested a new drug called MK-1200 in people with advanced cancers of the stomach, esophagus, bile ducts, or pancreas who had already tried all other treatments that could help them. The main goals were to find a safe dose and see if the drug could shrink tum…

This large, completed study tested whether a drug called pembrolizumab could help prevent kidney cancer from returning in patients who had their tumor surgically removed. Nearly 1,000 adults at high risk of the cancer coming back received either the drug or a placebo for about a …

This large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation treatment works better than chemoradiation alone for people with locally advanced head and neck cancer. The study enrolled 804 patients to see if the combinat…

This study tested if people with HIV who were already successfully controlling their virus could safely switch to a new, simpler once-daily pill (doravirine/islatravir). It compared this new combination to people who continued their current antiretroviral therapy. The main goal w…

This study tested a personalized mRNA vaccine combined with an immunotherapy drug for people with advanced skin cancer that could be removed by surgery. The goal was to see if giving this combination before and after surgery was better than standard care at keeping the cancer fro…

This large, completed Phase 3 trial tested if adding the drug lenvatinib to the standard immunotherapy pembrolizumab works better for adults with advanced melanoma who haven't had prior drug treatment. The goal was to see if the two-drug combination helps patients live longer and…

This study tested whether adding the drug ertugliflozin could help teens (ages 10-17) with type 2 diabetes better control their blood sugar. It involved 166 young people who were already taking metformin, with or without insulin. The main goal was to see if the new drug was safe …

This large, completed Phase 3 trial tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has returned or spread. The study involved 511 participants and aimed to see i…

This early-stage study tested the safety and how the body processes the antibiotic combination ceftolozane/tazobactam in children with hospital-acquired pneumonia. It involved 41 hospitalized children who were already receiving standard antibiotic care. The main goal was to see i…

This large, completed study tested if adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal cancer. The goal was to see if the combination, given both before and after surgery, helps keep the cancer from returning and i…

This study tested new drug combinations for people with melanoma skin cancer that had spread to the brain. The goal was to find treatments that are safer and work better than current options. It involved 56 participants and measured how well the tumors shrank and how long the res…

This study tested whether a combination of two drugs, lenvatinib and pembrolizumab, could help people live longer compared to standard chemotherapy. It involved 408 adults with advanced head and neck cancer that had continued to grow despite previous platinum-based chemotherapy a…

This early-stage study tested the safety and dosing of a new drug called ulevostinag, which is injected directly into tumors. It was tested alone and combined with the immunotherapy drug pembrolizumab in 156 people with advanced or spreading solid tumors or lymphomas. The main go…

This study tested whether a combination of two newer drugs (pembrolizumab and lenvatinib) works better than standard chemotherapy for women with advanced or recurrent endometrial (uterine) cancer. It involved 130 participants and directly compared how long patients lived without …

This study tested six different drug combinations in people with Stage III melanoma who were scheduled for surgery. The goal was to see if adding new experimental drugs to a standard immunotherapy (pembrolizumab) could shrink tumors more effectively and safely before the operatio…

This study tested several new drug combinations for people with advanced esophageal cancer that had worsened after one prior treatment. Researchers enrolled 90 participants to evaluate whether adding experimental drugs to existing immunotherapy (pembrolizumab) with chemotherapy o…

This large, completed Phase 3 study tested a new once-daily pill (doravirine/islatravir) for people newly diagnosed with HIV-1. It directly compared this new combination to a standard HIV treatment to see if it was as good or better at suppressing the virus and if it was safe. Th…

This large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to the standard first-line treatment (trastuzumab plus chemotherapy) could better control advanced HER2-positive stomach or gastroesophageal junction cancer. It involved 738 participant…

This study tested if a combination of olaparib and pembrolizumab works better than standard chemotherapy plus pembrolizumab for controlling advanced triple-negative breast cancer. It involved 462 people whose cancer had responded to initial treatment. The goal was to see which ap…

This first-in-human study tested the safety and early effectiveness of a new drug called vibostolimab. It was given alone and in combination with an existing immunotherapy (pembrolizumab) to 474 adults with advanced solid tumors that had stopped responding to other treatments. Th…

This study tested the safety and effectiveness of the drug vorinostat in people whose follicular lymphoma or similar slow-growing B-cell lymphomas had returned or stopped responding to previous treatments. It involved 56 participants who had tried up to four prior chemotherapy re…

This study tested two different ways to calculate the dose of a medication called sotatercept for people with pulmonary arterial hypertension (PAH), a serious lung disease. Researchers compared the standard weight-based dosing to a simpler weight-banded method in 164 participants…

This large study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy, both before and after surgery, works better than chemotherapy alone for triple negative breast cancer. It involved 1,174 patients with locally advanced disease who hadn't receive…

This completed Phase 3 trial tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for Chinese patients with advanced melanoma that has spread. The study involved 131 participants who had not received prior drug treatme…

This study tested whether adding an experimental drug called MK-4830 to standard immunotherapy and chemotherapy could better shrink tumors before surgery in people with high-grade ovarian cancer. Researchers measured tumor DNA in the blood to see if the new combination was more e…

This Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) would help men with metastatic prostate cancer that still responds to hormones. The study enrolled 186 Chinese participants and aimed to see if the co…

This large, completed Phase 3 trial tested whether adding a drug called lenvatinib to a standard immunotherapy (pembrolizumab) was better than the immunotherapy alone for people with advanced non-small cell lung cancer who had not yet received treatment. It involved 623 adults an…

This completed Phase 3 trial tested whether a new two-in-one immunotherapy drug (MK-4280A) works better than standard chemotherapy for Chinese adults with advanced colorectal cancer that had spread and stopped responding to prior treatments. The main goal was to see if the new tr…

This study tested if people with well-controlled HIV could switch from taking daily pills to a new weekly combination of two drugs, islatravir and ulonivirine. The goal was to see if the weekly treatment was safe and tolerable. However, the trial was stopped early because partici…

This large Phase 3 trial tested whether the drug vericiguat could help people with chronic heart failure live longer and avoid hospital stays. Over 6,000 adults with symptomatic heart failure participated, comparing vericiguat against a placebo. The main goal was to see if the dr…

This large, completed Phase 3 trial tested an oral drug called MK-0616 for adults with high cholesterol, including some with a genetic form. The main goal was to see if the drug was better than a placebo at lowering 'bad' LDL cholesterol over 24 weeks. Researchers also tracked si…

This large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy works better than standard treatment alone for women with high-risk, locally advanced cervical cancer. It involved over 1,000 participants and aimed to see…

This large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to the standard drug lenvatinib works better for adults with advanced liver cancer. The main goal was to see if the combination helps patients live longer without their cancer getting w…

This study tested if adding a drug called lenvatinib to the standard three-drug treatment (chemotherapy plus immunotherapy) works better for adults in China with advanced lung cancer that has spread. The main goals were to see if the four-drug combo could slow the cancer's growth…

This study tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced bladder cancer who cannot tolerate standard chemotherapy. It involved 505 participants and aimed to see if the combination helped…

This study tested whether a drug called pembrolizumab could help prevent a serious type of skin cancer from coming back after surgery and radiation. It involved 450 people with high-risk, locally advanced skin cancer who had completed their initial treatment. The main goal was to…

This study tested whether adding the drug pembrolizumab to standard supportive care helped Asian patients with advanced liver cancer live longer. It involved 453 people whose cancer had worsened after their first treatment. Participants were randomly assigned to receive either th…

This large, completed Phase 3 trial tested if adding a new drug (vibostolimab) to an existing immunotherapy (pembrolizumab) worked better than the standard single drug for people with a specific type of advanced lung cancer (PD-L1 positive NSCLC). Over 1,200 participants were ran…

This study tested whether giving the immunotherapy drug pembrolizumab every six weeks could help control two types of lymphoma that had returned or stopped responding to previous treatments. It involved 66 adults with relapsed Hodgkin's lymphoma or primary mediastinal large B-cel…

This study tested whether adding a new drug (MK-1454) directly into tumors, alongside a standard immunotherapy drug (pembrolizumab), works better than the standard drug alone for advanced head and neck cancer. It involved 18 adults whose cancer had spread or returned and could no…

This study tested whether a new two-drug combination called MK-4280A works better than standard treatments for people with advanced colorectal cancer that has spread and stopped responding to prior therapies. It involved 441 participants whose cancer tested positive for a specifi…

This study tested a new antibiotic combination (imipenem/cilastatin/relebactam) in children from birth to under 18 years old who had serious, confirmed or suspected bacterial infections. The main goals were to check if the treatment was safe and to see how well it worked compared…

This large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps women with advanced cervical cancer that has returned or spread. The study involved 617 women and aimed to see if the combination could help them live lon…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal junction cancer. It involved 120 Chinese adults who hadn't received prior treatment, giving the drug combination both before and after surg…

This early-stage study tested a new oral drug called MK-5684 (opevesostat) in 14 Chinese men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The main goals were to check the drug's safety, see how well it was tolerated, and mea…

This study was the first to test the safety and early effects of an experimental drug called nemtabrutinib in Japanese adults with advanced B-cell blood cancers. It involved a small group of participants whose previous treatments had stopped working. The main goal was to find a s…

This completed Phase 3 trial tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has returned or spread. It involved 112 participants whose cancer had a specific mark…

This large, completed Phase 3 trial tested if adding a new drug (vibostolimab) to a standard immunotherapy (pembrolizumab) and chemotherapy works better than the standard treatment alone for people newly diagnosed with advanced non-small cell lung cancer that has spread. The main…

This study tested whether a new two-drug combination (favezelimab/pembrolizumab) could help people with classical Hodgkin lymphoma live longer without their cancer getting worse, compared to standard chemotherapy. It focused on patients whose cancer had returned or stopped respon…

This study compared two different drugs for people whose Hodgkin lymphoma returned or didn't respond to previous treatment. Researchers tested whether pembrolizumab (an immunotherapy drug) worked better than brentuximab vedotin (a targeted therapy) at keeping the cancer from prog…

This study tested whether the drug efinopegdutide could help adults with nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Researchers compared the drug against a placebo in 381 participants over 52 weeks to see if it could clear liver inflammation witho…

This large, completed Phase 3 trial tested whether adding a drug called olaparib to a standard immunotherapy and chemotherapy regimen could better control advanced squamous non-small cell lung cancer. It involved 851 people with newly diagnosed, advanced disease that had spread. …

This study tested pembrolizumab, an immunotherapy drug, for people with high-risk bladder cancer that didn't respond to standard BCG treatment and who couldn't or wouldn't have bladder removal surgery. The trial involved 296 participants and aimed to see if pembrolizumab alone or…

This study tested a new combination of two immunotherapy drugs (pembrolizumab and vibostolimab) for people with advanced blood cancers that had returned or stopped responding to other treatments. The main goals were to check the safety of the treatment and see how well it worked …

This study tested an oral drug called lenvatinib in children, teens, and young adults whose solid tumors had returned or stopped responding to standard treatments. It involved 127 participants with various cancers, including certain sarcomas and brain tumors. The main goal was to…

This large, completed Phase 3 trial tested if adding a new drug (vibostolimab) to a standard immunotherapy (pembrolizumab) works better than the standard drug alone to prevent melanoma from coming back after surgery. It involved 1,594 people with high-risk melanoma who had their …

This large, completed Phase 3 trial tested two different drug combinations for people with advanced non-squamous non-small cell lung cancer (NSCLC) that had spread. After initial treatment, over 1,000 participants were randomly assigned to receive one of two maintenance therapies…

This large, completed Phase 3 trial tested if a new combination of two immunotherapy/targeted drugs (enfortumab vedotin plus pembrolizumab) given before and after surgery works better than the current standard chemotherapy (gemcitabine plus cisplatin) for people with muscle-invas…

This study tested the safety and initial effectiveness of a two-drug combination (favezelimab and pembrolizumab) for people with certain blood cancers, including Hodgkin lymphoma and non-Hodgkin lymphoma. It involved 137 participants to find a safe dose and see if the treatment c…

This study tested the safety and effectiveness of combining two drugs, pembrolizumab and lenvatinib, in people with advanced solid tumors that had stopped responding to standard treatments. It involved 611 participants with cancers like triple-negative breast, ovarian, gastric, c…

This large, completed Phase 3 study tested whether a drug called pembrolizumab could help prevent liver cancer (hepatocellular carcinoma) from returning in people who had their initial tumor completely removed by surgery or ablation. The study involved 959 participants who receiv…

This study tested whether adding new experimental drugs to an existing immunotherapy (pembrolizumab) could better control advanced non-small cell lung cancer in patients who had not yet received any treatment for their metastatic disease. It involved 102 participants whose cancer…

This study tested whether a new two-drug combination works better than the standard single-drug treatment for advanced kidney cancer that has spread. It involved 861 people who had not yet received treatment for their advanced cancer. Researchers compared the combination of pembr…

This large, completed Phase 3 trial tested whether adding a drug called lenvatinib to the standard first treatment (chemotherapy plus pembrolizumab) could better control advanced non-small cell lung cancer that had spread. It involved 761 adults and aimed to see if the four-drug …

This study tested whether a combination of two drugs, lenvatinib and pembrolizumab, could help people live longer than the standard treatments for metastatic colorectal cancer that has stopped responding to prior therapies. It involved 563 participants whose cancer had spread and…

This study tested whether an experimental drug called MK-0616 could lower 'bad' cholesterol (LDL-C) better than a placebo in adults with a genetic form of high cholesterol. Over 300 participants who were already on standard cholesterol medication received either the drug or a dum…

This study tested a new preventive antibody drug called clesrovimab to see if it is safe and works as well as the standard treatment (palivizumab) for preventing severe RSV disease. It involved over 1,000 infants and children who are at high risk for serious RSV infections. Resea…

This study tested the safety and how the body processes a new monthly oral pill, MK-8527, intended to help prevent HIV infection. It involved 352 adults at low risk for HIV who took either the pill or a placebo for comparison. The main goal was to see how well the pill was tolera…

This study tested whether an experimental drug called MK-2060 could prevent dangerous blood clots from forming in the artificial grafts used for dialysis in people with kidney failure. Over 500 participants received either one of two doses of the drug or a placebo to see which wo…

This study tested a single shot called clesrovimab (MK-1654) to see if it could prevent serious lower respiratory infections caused by RSV in healthy babies. Over 3,600 infants, including those born prematurely, received either the shot or a placebo. The main goal was to see if t…

This study tested whether a new pneumonia vaccine (V116) is safe and works as well when given at the same time as the annual flu shot, compared to giving them separately. It involved over 1,000 adults aged 50 and older. The main goal was to see if getting both shots together is j…

This early-stage study tested whether a very high dose of a new monthly oral pill for preventing HIV infection could affect heart rhythm. It involved 42 healthy adult volunteers to check for safety signals, particularly any changes to the electrical activity of the heart. The mai…

This study tested whether a vaccine called V114 could prevent certain types of painful ear infections in young children. Over 7,000 healthy babies around 2 months old participated to see if the vaccine reduced ear infections caused by specific bacteria. Researchers also carefully…

This study tested a new vaccine called V116 designed to prevent pneumococcal disease, a serious type of bacterial pneumonia, in adults living with HIV. It involved 313 participants and compared the new vaccine's safety and immune response to an existing vaccine combination. The g…

This early-stage study aimed to understand how the body processes a new drug called MK-1084 (calderasib). Researchers tested 56 healthy adults to see if taking the drug with food, in a different pill form, or alongside common stomach acid medicine changed how much of the drug got…

This study aimed to understand how drinking coffee or tea affects the way the body processes an experimental drug called enlicitide. Researchers tested 60 healthy adults, comparing blood levels of the drug when taken with coffee, tea, or just water. The goal was to see if these c…

This study aimed to understand how two different forms of the drug sotatercept behave in the body. Researchers compared a new liquid version given with an auto-injector pen to an older, freeze-dried version. The study involved 146 healthy female volunteers who could not become pr…

This study aimed to understand how the experimental drug MK-5684 is processed by the body in men with severe or end-stage kidney disease. Researchers compared drug levels in the blood of 24 men—some with kidney disease and some healthy—after a single dose. The goal was to see if …

This study aimed to understand how much of two HIV medications, doravirine and islatravir, pass into breast milk. Researchers measured drug levels in the breast milk and blood of 12 healthy, breastfeeding women over 24 hours after they took a single dose. The goal was to gather s…

This study aimed to understand how an experimental drug called MK-8527 is processed by the body in people with mild or moderate liver impairment. Researchers compared the drug's behavior in 18 participants—some with liver problems and some healthy. The goal was to gather safety i…

This study tested a drug called calderasib in healthy adults. Researchers compared how the body absorbs two different pill versions. They also checked if taking the pill with or without food changes how it works in the body.

This early-stage study aimed to understand how a new lung cancer drug candidate, calderasib, interacts with two common medications (midazolam and digoxin) in the body. Researchers gave healthy volunteers the new drug along with the other medicines to see if it changed how their b…

This study tested how an experimental HIV drug called MK-4646 interacts with a common tuberculosis medication called rifabutin. Researchers gave both drugs to 18 healthy volunteers to measure how rifabutin affects MK-4646 levels in the blood and to check for safety issues. The go…

This study aimed to understand how moderate to severe kidney problems affect how the body processes an experimental drug called MK-8527. It involved 18 people, some with kidney impairment and some with healthy kidneys, who each received a single dose. Researchers measured how muc…

This study aimed to understand how a drug for fatty liver disease (NASH) is processed by the body in people with moderate to severe liver damage. Researchers compared 22 participants—some with liver impairment and some healthy—after they received a single dose. The main goal was …

This study aimed to understand how a new drug candidate called Ulonivirine moves through a healthy person's body. Eight healthy volunteers received a single dose containing a tiny, safe amount of radioactive tracer to help researchers track it. The main goal was to measure how th…

This study looked at how a new prostate cancer drug, opevesostat, is processed by the body in men with moderate liver problems compared to healthy men. Researchers gave a single dose to 16 participants and measured drug levels in their blood over time to understand if liver impai…

This study aimed to understand how a new drug called calderasib (MK-1084) might change how the body processes two common medications: rosuvastatin (a cholesterol drug) and metformin (a diabetes drug). It involved 16 healthy participants who took the medications with and without c…

This study aimed to understand how two common medications (itraconazole and phenytoin) affect how the body processes a single dose of an experimental drug called MK-1084 (calderasib). It involved 28 healthy adult participants to measure drug levels in the blood and check for safe…

This study aimed to understand how a cancer drug called belzutifan might change the way the body processes metformin, a common diabetes medication. It involved 14 healthy adult volunteers who took metformin alone and then with belzutifan. Researchers measured the levels of metfor…

This study aimed to understand how a damaged liver processes an experimental drug called bomedemstat (MK-3543). Nine participants, some with mild or moderate liver problems and some healthy, took a single dose. Researchers tracked how much of the drug stayed in their blood over t…

This early-stage study aimed to understand how the body processes and eliminates an experimental drug called MK-5475. Eight healthy male volunteers received a single intravenous dose containing a tiny radioactive tracer. Researchers then measured how much of the drug was broken d…

This study aimed to understand how a drug called calderasib (MK-1084) behaves in people with moderate to severe kidney problems compared to healthy people. Researchers gave a single dose to 34 participants and measured drug levels in their blood and urine over time. The goal was …

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil \[FP regimen\] or oxaliplatin combined with capecitabine \[CAPOX regimen\]) versus placebo in combination with chemotherapy (F…